

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (currently amended) Peptide nucleic acid (PNA) complementary to the antisense or sense strand of human N-myc gene, wherein ~~comprising 12 to 24 nucleotide bases~~, said peptide nucleic acid is SEQ ID NO: 3 being complementary to the exon 2 sequence of N-myc gene, or said peptide nucleic acid is SEQ ID NO: 1 being an only sequence complementary to 5'-UTR region antisense-strand of human N-myc gene.

2. (cancelled)

3. (previously presented) The peptide nucleic acid (PNA) according to claim 1, in which PNA is conjugated with a carrier that can get through the nuclear membrane of target cells expressing N-myc gene.

4. (previously presented) The conjugated peptide nucleic acid (PNA) according to claim 3, in which said carrier is conjugated at 3' end of PNA sequence.

5. (currently amended) The peptide nucleic acid (PNA) according to claim ~~[[1]]~~ 3, in which said carrier is chosen among the following peptide sequences:

SEQ ID NO: 8;

SEQ ID NO: 9;

SEQ ID NO: 10;

SEQ ID NO: 11;

SEQ ID NO: 12;

SEQ ID NO: 13;

SEQ ID NO: 14;

SEQ ID NO: 15;

SEQ ID NO: 16.

6-7. (cancelled)

8. (previously presented) The peptide nucleic acid (PNA) according to claim 1, in which sense anti-gene PNA is conjugated in 3' with SEQ ID NO: 8.

9. (previously presented) A pharmaceutical composition comprising a peptide nucleic acid PNA according to claim 1.

10-17. (cancelled)